Chief Executive Officer at Life Biosciences
Jerry McLaughlin is chief executive officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as president and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of senior vice president & chief commercial officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches.
He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.
See also: Life Biosciences - Drug development company promoting longevity and finding treatments for age-related diseases
Jerry McLaughlin is also referenced in the following:
28-Aug-2023 to 01-Sep-2023
Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen
Jerry McLaughlin News
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023
Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few yearsRead more...
Life Biosciences raises funding to develop innovative therapies against ageing biology
Longevity Technology - 06-Jan-2022
Invests $82 million in research platforms, aiming to prevent or reverse age-related diseasesRead more...